If you have been reading about anti-doping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
=== Endometrium === The endometrium after the process of breakdown via the menstruation cycle, re-epithelializes swiftly and regenerates. Though tissues with a non-interrupted morphology, like non-injured soft tissue, completely regenerate consistently; the endometrium is the only human tissue that completely regenerates consistently after a disruption and interruption of the morphology. The inner lining of the uterus is the only adult tissue to undergo rapid cyclic shedding and regeneration without scarring, shedding and restoring roughly inside a 7-day window on a monthly basis. All other adult tissues, upon rapid shedding or injury, can scar.
Twin Peaks was founded in 2005 by Randy Dewitt and Scott Gordon in Lewisville, Texas. Dewitt, who had previously helped Brinker International develop Rockfish Seafood, noted a thriving sports-bar market and decided to create a chain with a mountain-lodge motif and attractive servers. According to analysts, 'breastaurant' chains have been growing at a rate of 30-40% per year, while the general restaurant industry as a whole has only grown about 3-5% annually. By August 2013, Twin Peaks had expanded to 38 locations across 17 states in the United States. Most locations are in Texas, with others in the American Southwest, Midwest and South. Twin Peaks has a mix of franchised and corporate-owned restaurants. In 2014, Bloomberg recognized Twin Peaks as "one of the nation’s fastest-growing restaurant chains". By August 2018, Twin Peaks had 84 locations, 54 franchised, 30 company operated, and sales of $322 million with the 85th Twin Peaks opening in Toledo, Ohio. Twin Peaks plans to open 10-12 restaurants in 2021, after reporting strong profit during the COVID-19 pandemic. On September 1, 2020, Twin Peaks announced that it would be acquired by FAT Brands, owner of Fatburger and Johnny Rockets, for $300 million. The acquisition was completed on October 1. On January 26, 2026, parent company FAT Brands filed for Chapter 11 bankruptcy protection in an effort to shed billions of dollars in debt. The company listed assets and liabilities between $1 billion and $10 billion. On June 15, 2026, Twin Peaks announced it had emerged from the Chapter 11 process.
A distinction is made between two primary types of joint work. In the case of mink'a, people work together for projects of common interest (such as the construction of communal facilities). Ayni is, in contrast, reciprocal assistance, whereby members of an ayllu help a family to accomplish a large private project, for example, house construction, and in turn can expect to be similarly helped later with a project of their own. In almost all Quechua ethnic groups, many traditional handicrafts are an important aspect of material culture. This includes a tradition of weaving handed down from Inca times or earlier, using cotton, wool (from llamas, alpacas, guanacos, and vicuñas), and a multitude of natural dyes, and incorporating numerous woven patterns (pallay). Houses are usually constructed using air-dried clay bricks (tika, or in Spanish adobe), or branches and clay mortar ("wattle and daub"), with the roofs being covered with straw, reeds, or puna grass (ichu). The disintegration of the traditional economy, for example, regionally through mining activities and accompanying proletarian social structures, has usually led to a loss of both ethnic identity and the Quechua language. This is also a result of steady migration to large cities (especially Lima), which has resulted in acculturation by Hispanic society there.
Sources: en.wikipedia.org
== L == Lac repressor – lactic acid autotroph – lagging strand – lambda phage – larva – leading strand – leaf – White blood cells – lichen – life form – life – light reactions – limbic system – limnology – Lineweaver-Burk diagram – lipase – lipid – liver – locus – long-term potentiation – Louis Pasteur – lung – Lynn Margulis – Lyon hypothesis – lysis – lysozyme – lytic cycle
=== Sport === Paul Frère (1917–2008), Belgian racing driver Wilfried Nancy (born 1977), football manager Jérôme Le Banner (born 1972), kickboxer and K-1 fighter Vikash Dhorasoo, (born 1973), international footballer Olivier Davidas (born 1981), footballer Dimitri Dragin (born 1984), judoka Julien Faubert (born 1983), footballer Kevin Anin (born 1986), footballer Gueïda Fofana (born 1991), footballer Jaylen Hoard (born 1999), French-American basketball player for Hapoel Tel Aviv Dan Delaunay (born 1995), professional footballer.
De emerges, in retrospect, as a modest self-effacing scientist driven by inner compulsions to grapple with a major scientific problem of the time. His choice of cholera as his field of interest was remarkably appropriate to his setting. To this problem De brought a wonderfully thoughtful approach, together with deep intuition, enabling him to make the long-awaited breakthrough in the field."
Without the fully functional sar1B protein, the COPll coatomer proteins engulf pre-chylomicrons exiting the ER but are unable to disassemble upon arrival at the cis-Golgi, preventing membrane fusion with this organelle.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.